Shanghai Rendu Valuation Multiples

Discover revenue and EBITDA valuation multiples for Shanghai Rendu.

Shanghai Rendu Overview

About Shanghai Rendu

Shanghai Rendu Biotechnology Co Ltd provides solutions for accurate diagnosis, effective prevention and control, as well as personalized diagnosis and treatment of pathogens in the areas of reproduction, respiration, digestion, blood, food, and environmental safety.


Founded

2007

HQ

China

Employees

N/A

Website

rdbio.com

Financials (FY)

Revenue: $24M
EBITDA: $4M

EV

$178M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Shanghai Rendu Financials

Shanghai Rendu reported last fiscal year revenue of $24M and EBITDA of $4M.

In the same fiscal year, Shanghai Rendu generated $19M in gross profit, $4M in EBITDA, and $1M in net income.


Shanghai Rendu P&L

In the most recent fiscal year, Shanghai Rendu reported revenue of $24M and EBITDA of $4M.

Shanghai Rendu is profitable as of last fiscal year, with gross margin of 78%, EBITDA margin of 17%, and net margin of 6%.

See analyst estimates for Shanghai Rendu
Last FY202320242025202620272028
Revenue$24M$24M$26M$24M
Gross Profit$19M$20M$21M$19M
Gross Margin78%81%79%78%
EBITDA$4M$3M$325K$4M
EBITDA Margin17%13%1%17%
EBIT Margin(9%)(5%)(7%)(9%)
Net Profit$1M$1M($1M)$1M
Net Margin6%5%(4%)6%

Financial data powered by Morningstar, Inc.

Shanghai Rendu Stock Performance

Shanghai Rendu has current market cap of $294M, and enterprise value of $178M.


Shanghai Rendu's stock price is $7.33.

Shanghai Rendu has an EPS (earnings per share) of $0.04.

See more trading valuation data for Shanghai Rendu
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$178M$294M0.3%---$0.04

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Shanghai Rendu Valuation Multiples

Shanghai Rendu trades at 7.4x EV/Revenue multiple, and 44.6x EV/EBITDA.

See NTM and 2027E valuation multiples for Shanghai Rendu

Shanghai Rendu Financial Valuation Multiples

As of August 14, 2026, Shanghai Rendu has market cap of $294M and EV of $178M.

Shanghai Rendu has a P/E ratio of 196.3x.

Last FY202320242025202620272028
EV/Revenue7.4x7.3x6.8x7.4x
EV/EBITDA44.6x57.1xn/m44.6x
EV/EBIT(84.0x)(144.0x)(99.1x)(84.0x)
EV/Gross Profit9.5x9.0x8.5x9.5x
P/E196.3x239.8xn/m196.3x
EV/FCF78.1xn/m86.4x78.1x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Shanghai Rendu Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Shanghai Rendu Margins & Growth Rates

In the most recent fiscal year, Shanghai Rendu reported gross margin of 78%, EBITDA margin of 17%, and net margin of 6%.

See estimated margins and future growth rates for Shanghai Rendu

Shanghai Rendu Margins

Last FY20242025202720282029
Gross Margin78%79%78%
EBITDA Margin17%1%17%
EBIT Margin(9%)(7%)(9%)
Net Margin6%(4%)6%
FCF Margin9%8%9%

Shanghai Rendu Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth8%(9%)
Gross Profit Growth5%(10%)
EBITDA Growth(90%)1126%
EBIT Growth45%18%
Net Profit Growth(195%)(229%)
FCF Growth(534%)11%

Data powered by FactSet, Inc. and Morningstar, Inc.

Shanghai Rendu Operational KPIs

Access forward-looking KPIs for Shanghai Rendu
Last FY202320242025202620272028
S&M Expenses to Revenue27%28%27%27%
G&A Expenses to Revenue4%4%5%4%
R&D Expenses to Revenue21%25%22%21%
Opex to Revenue87%86%86%87%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Shanghai Rendu Competitors

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E

This data is available for Pro users. Sign up to see all Shanghai Rendu competitors and their valuation data.

Start Free Trial

Shanghai Rendu VC Funding History

Before going public, Shanghai Rendu raised $14M in total equity funding, across 3 rounds.


Shanghai Rendu Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Jun-19Seed-$2M--
Mar-16Series BQiming Venture Partners$2M--
Dec-13Series BQiming Venture Partners; Huagai Capital$10M-Shanghai Rendu Biotechnology, also known as Rendu Biotechnology, is a leader in RNA molecular diagnostics in China, specializing in innovative products using its SAT technology platform, including the AutoSAT fully automatic high-throughput nucleic acid detection system. Qiming Venture Partners was the earliest investor and led the company's Series A financing round in 2013. Prior to its 2022 IPO on the STAR Market, Qiming held a 24% stake as the largest institutional investor. A Series B round occurred on November 30, 2013, raising $10.28 million from Huagai Capital and Qiming Venture Partners.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Shanghai Rendu

When was Shanghai Rendu founded?Shanghai Rendu was founded in 2007.
Where is Shanghai Rendu headquartered?Shanghai Rendu is headquartered in China.
Is Shanghai Rendu publicly listed?Yes, Shanghai Rendu is a public company listed on Shanghai Stock Exchange.
What is the stock symbol of Shanghai Rendu?Shanghai Rendu trades under 688193 ticker.
When did Shanghai Rendu go public?Shanghai Rendu went public in 2022.
Who are competitors of Shanghai Rendu?Shanghai Rendu main competitors include
What is the current market cap of Shanghai Rendu?Shanghai Rendu's current market cap is $294M.
What is the current revenue of Shanghai Rendu?Shanghai Rendu's last fiscal year revenue is $24M.
What is the current EV/Revenue multiple of Shanghai Rendu?Current revenue multiple of Shanghai Rendu is 7.4x.
Is Shanghai Rendu profitable?No, Shanghai Rendu is not profitable.
How many companies Shanghai Rendu has acquired to date?Shanghai Rendu hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Shanghai Rendu has invested to date?Shanghai Rendu hasn't invested in any companies yet (or none have been disclosed publicly).

Lists including Shanghai Rendu

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial